Yu Liang

US Patent:

20110144184, Jun 16, 2011

Filed:

Jul 23, 2009

Appl. No.:

13/055587

Inventors:

Thomas Kristie - Silver Spring MD, US
Yu Liang - Rockville MD, US

Assignee:

The United States of America, as rep. by the Secretary, Dept of HHS - Bethesda MD

International Classification:

A61K 31/7105
A61K 31/135
A61K 31/137
A61K 31/15
A61K 31/42
A61P 31/12
A61P 31/20
A61P 31/22

US Classification:

514 44 A, 514647, 514655, 514654, 514378

Abstract:

An embodiment of the invention provides preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5.

US Patent:

20130123344, May 16, 2013

Filed:

Jan 22, 2013

Appl. No.:

13/747406

Inventors:

The United States of America, as Represented by the Secretary, Department of Health and Human Services - Bethesda MD, US
Yu Liang - Gaithersburg MD, US
Jodi Vogel - Bethesda MD, US
David J. Maloney - Point of Rocks MD, US
Anton Simeonov - Bethesda MD, US
Ajit Jadhav - Chantilly VA, US

Assignee:

The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD

International Classification:

A61K 31/551
C07D 215/14
A61K 31/506
A61K 31/5377
A61K 31/47
A61K 31/496

US Classification:

514 44 A, 514312, 51425307, 514256, 5142352, 514218, 546170, 546174, 544363, 544333, 544128, 540575

Abstract:

Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I):wherein R, R, R, R, and Rare as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for example, a compound of the formula (I). The viral infection may be a primary infection, reactivation of a virus after latency in a host, or may be in a mammal that has undergone, is undergoing, or will undergo immunosuppressive therapy.

US Patent:

20210024630, Jan 28, 2021

Filed:

Mar 26, 2019

Appl. No.:

17/040513

Inventors:

- Redmond WA, US
- Chengdu, Sichuan, CN
Dong XIA - Redmond WA, US
David JELLYMAN - Duvall WA, US
Katrina BYKOVA - Seattle WA, US
Anne-Marie ROUSSEAU - Seattle WA, US
Bill BRADY - Bothell WA, US
Blair RENSHAW - Renton WA, US
Brian KOVACEVICH - Snohomish WA, US
Yu LIANG - Redmond WA, US
Camilla WANG - Sammamish WA, US
Zeren GAO - Redmond WA, US
Hui Huang - Redmond WA, US

International Classification:

C07K 16/28
A61P 35/02
C12N 5/0783
C12N 5/09

Abstract:

The application provides guidance and navigation control (GNC) proteins. In one embodiment, the guidance and navigation control (GNC) protein, comprising a binding domain for a T cell activating receptor, a binding domain for a tumor associated antigen, a bind domain for an immune checkpoint receptor, and a binding domain for a T cell co-stimulating receptor. The binding domain for the tumor associated antigen is not adjacent to the binding domain for the T cell co-stimulating receptor. In one embodiment, the binding domain for the T cell activating receptor is adjacent to the binding domain for the tumor associated antigen (TAA).

US Patent:

20200157213, May 21, 2020

Filed:

Jun 22, 2018

Appl. No.:

16/615117

Inventors:

- Redmond WA, US
- Chengdu, CN
Dong XIA - Redmond WA, US
David JELLYMAN - Duvall WA, US
Katrina BYKOVA - Seattle WA, US
Anne-Marie K. ROUSSEAU - Seattle WA, US
Bill BRADY - Bothell WA, US
Blair RENSHAW - Renton WA, US
Brian KOVACEVICH - Snohomish WA, US
Yu LIANG - Redmond WA, US
Zeren GAO - Redmond WA, US

International Classification:

C07K 16/28
A61K 47/68
A61K 39/395
A61K 45/06

Abstract:

The application provides tri-specific antibody monomers having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fab domain, a Fc domain, and a second scFv domain at the C-terminal. In one embodiment, the first scFv domain, the Fab domain, and the second scFv domain each has a binding specificity against a different antigen.

US Patent:

20200157224, May 21, 2020

Filed:

Jun 22, 2018

Appl. No.:

16/615123

Inventors:

- Redmond WA, US
- Chengdu, CN
Dong XIA - Redmond WA, US
David JELLYMAN - Duvall WA, US
Katrina BYKOVA - Seattle WA, US
Anne-Marie K. ROUSSEAU - Seattle WA, US
Bill BRADY - Bothell WA, US
Blair RENSHAW - Renton WA, US
Brian KOVACEVICH - Snohomish WA, US
Yu LIANG - Redmond WA, US
Zeren GAO - Redmond WA, US

International Classification:

C07K 16/28
C07K 16/32
A61K 35/16

Abstract:

The disclosure provides a tetra-specific antibody monomer having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a second scFv domain, a Fab domain, a Fc domain, and a third scFv at the C-terminal, wherein the first scFv domain, the second scFv domain, the Fab domain, and the third scFv domain each has a binding specificity against a different antigen. In one embodiment, the antigen is a tumor antigen, an immune signaling antigen, or a combination thereof. In one embodiment, the antigen includes CD19, CD3, CD137, 4-1BB, and PD-L1. Multi-specific antibodies comprising the disclosed tetra-specific antibodies are also provided.

US Patent:

20160048754, Feb 18, 2016

Filed:

Aug 24, 2015

Appl. No.:

14/834274

Inventors:

- Mountain View CA, US
Yu Liang - Santa Clara CA, US
Ke Yang - Cupertino CA, US
Kai Chen - San Bruno CA, US

International Classification:

G06N 3/04
G06F 17/30
G06N 7/00
G06F 3/0484

Abstract:

Methods, systems, and apparatus, including computer programs encoded on computer storage media, for scoring concept terms using a deep network. One of the methods includes receiving an input comprising a plurality of features of a resource, wherein each feature is a value of a respective attribute of the resource; processing each of the features using a respective embedding function to generate one or more numeric values; processing the numeric values using one or more neural network layers to generate an alternative representation of the features, wherein processing the floating point values comprises applying one or more non-linear transformations to the floating point values; and processing the alternative representation of the input using a classifier to generate a respective category score for each category in a pre-determined set of categories, wherein each of the respective category scores measure a predicted likelihood that the resource belongs to the corresponding category.

US Patent:

20150073039, Mar 12, 2015

Filed:

Nov 17, 2014

Appl. No.:

14/543321

Inventors:

- Bethesda MD, US
Yu Liang - Rockville MD, US
Jodi Vogel - Bethesda MD, US

International Classification:

C12N 15/113

US Classification:

514 44 A

Abstract:

An embodiment of the invention provides a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides a method of preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides a method of preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5.

US Patent:

20140279774, Sep 18, 2014

Filed:

Mar 13, 2013

Appl. No.:

13/802462

Inventors:

- Mountain View CA, US
Yu Liang - Santa Clara CA, US
Ke Yang - Cupertino CA, US
Kai Chen - Brisbane CA, US

Assignee:

Google Inc. - Mountain View CA

International Classification:

G06N 3/02

US Classification:

706 20

Abstract:

Methods, systems, and apparatus, including computer programs encoded on computer storage media, for scoring concept terms using a deep network. One of the methods includes receiving an input comprising a plurality of features of a resource, wherein each feature is a value of a respective attribute of the resource; processing each of the features using a respective embedding function to generate one or more numeric values; processing the numeric values using one or more neural network layers to generate an alternative representation of the features, wherein processing the floating point values comprises applying one or more non-linear transformations to the floating point values; and processing the alternative representation of the input using a classifier to generate a respective category score for each category in a pre-determined set of categories, wherein each of the respective category scores measure a predicted likelihood that the resource belongs to the corresponding category.